Acquisition traction Pregistry is now part of CorEvitas, following a 2023 acquisition, signaling potential access to broader clinical data networks and larger enterprise deals within pregnancy safety and regulatory affairs.

Regulatory specialization The company focuses on regulatory requirements for drug and vaccine safety during pregnancy, presenting a clear entry point for sales conversations around compliance support, post-marketing surveillance, and observational studies.

Clinical leadership Appointment of a Chief Medical Officer and a track record in observational studies suggest credibility with pharma R&D and safety pharmacovigilance teams, aiding trust-building in pilot collaborations.

Moderate scale With 51-200 employees and annual revenue in the low-to-mid single digits, there is room for scalable, near-term contracts and pilot projects that expand services without large enterprise bids.

Digital and data readiness Technical stack and data capabilities (AWS, data sources, registries) indicate readiness for integration with sponsor data ecosystems, offering opportunities for data provisioning, analytics, and registry-based studies.